Compare ARDX & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | CRTO |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Advertising |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 797.8M | 751.6M |
| IPO Year | 2014 | 2013 |
| Metric | ARDX | CRTO |
|---|---|---|
| Price | $3.02 | $14.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $12.80 | ★ $20.05 |
| AVG Volume (30 Days) | ★ 4.3M | 295.4K |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.95 |
| EPS | N/A | ★ 0.37 |
| Revenue | $2,607,000.00 | ★ $2,296,692,000.00 |
| Revenue This Year | $19.21 | N/A |
| Revenue Next Year | $28.19 | $1.85 |
| P/E Ratio | ★ N/A | $39.54 |
| Revenue Growth | N/A | ★ 27.65 |
| 52 Week Low | $2.96 | $13.95 |
| 52 Week High | $8.40 | $25.29 |
| Indicator | ARDX | CRTO |
|---|---|---|
| Relative Strength Index (RSI) | 37.18 | 45.95 |
| Support Level | N/A | $14.12 |
| Resistance Level | $3.35 | $15.85 |
| Average True Range (ATR) | 0.13 | 0.58 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 15.19 | 53.83 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.